The characteristics and the multiple functions of integrin β1 in human cancers

Table 4 Integrin β1-targeting cancer therapies in clinical trials

Drug name	Drug type	Source	Target	Indication	Study status
Volociximab	Antibody	NCT00099970; NCT00100685; NCT00278187; NCT00369395; NCT00401570; NCT00516841	α5β1	Non-small cell lung cancer; pancreatic cancer; epithelial ovarian cancer or primary peritoneal cancer; renal cell carcinoma; melanoma	Phase II (terminated)
MINT-1526A	Antibody	NCT01139723	α5β1	Solid tumors	Phase I
PF-4605412	Antibody	NCT00915278	α5β1	Solid tumors	Phase I (terminated)
OS2966	Antibody	NCT04608812	β1	Glioma	Phase I
Pegylated recombinant human endostatin	Peptide	NCT01527864	α5β1	Non-small cell lung cancer	Phase II
Ac-PHSCN-NH2	Peptide	NCT00131651	α5β1	Renal cell cancer	Phase II (terminated)
AS-101	Small molecule	NCT00418249; NCT00788424; NCT00927212; NCT00926354; NCT01010373; NCT01555112; NCT01943630; NCT03216538	α4β1	Acute myeloid leukemia	Phase II (terminated)
GLPG-0187	Small molecule	NCT00928343; NCT01313598; NCT01580644	α5β1	Solid tumors	Phase I
7HP-349	Small molecule	NCT04508179	α4β1	Solid tumors	Phase I
BA 015 gene therapy	Gene therapy	NCT01764009	α5β1	Melanoma	Phase II (terminated)

Source of clinical trials information: ClinicalTrials.gov. All information is current as of October 2023. Trials in healthy volunteers only are excluded

ISSN: 1479-5876